Anal, Rectal (e.g., Suppositories, Etc.) Patents (Class 424/436)
  • Patent number: 7341737
    Abstract: A tampon adapted to deliver a therapeutic agent, the tampon including a tampon body having a distal end; and a dosage form affixed to the distal end of the tampon body, wherein the dosage form includes a formulation including a therapeutic agent, and wherein the dosage form comprises a plurality of layers. Also, a method for manufacturing a medicated tampon adapted to deliver a therapeutic agent, the method including manufacturing a tampon body having a distal end; producing a dosage form having a plurality of layers, wherein the dosage form includes a formulation including a therapeutic agent; and affixing the dosage form to the distal end of the tampon body.
    Type: Grant
    Filed: December 31, 2002
    Date of Patent: March 11, 2008
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Steven Craig Gehling, Donald C. Harrison, James H. Liu, Wolfgang A. Ritschel, Chris Clendening, Giovanni M. Pauletti
  • Patent number: 7332177
    Abstract: A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: February 19, 2008
    Assignee: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Nava Zisapel, Moshe Laudon
  • Patent number: 7320800
    Abstract: The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the wetted, micronized progesterone; mixing the dry micronized progesterone with other pharmaceutically acceptable excipients or diluents; and; forming a tablet by direct compaction of the dry micronized progesterone. Tablets prepared by this method are also provided.
    Type: Grant
    Filed: January 12, 2005
    Date of Patent: January 22, 2008
    Assignee: Ferring B.V.
    Inventor: Azariah Jossifoff
  • Patent number: 7255881
    Abstract: Metal-containing materials, as well as their preparation and use are disclosed. The metal-containing material can be, for example, an antimicrobial material, an anti-biofilm material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, anti-proliferative, MMP modulating material, an atomically disordered, crystalline material, and/or a nanocrystalline material. In certain embodiments, the metal-containing material is an atomically disordered, nanocrystalline silver-containing material.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: August 14, 2007
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Scott H. Gillis, Paul Schechter, James Alexander Robert Stiles
  • Patent number: 7226622
    Abstract: Novel methods for the chemical ablation of tissue (e.g. prostatic tissue) are described. These methods include the steps of: (a) providing one or more solid salt dosage form comprising 50-100% w/w salt; and (b) inserting one or more of such solid salt dosage forms into the tissue. The solid salt dosage form is optionally inserted into the tissue under real-time ultrasonic observation. An advantage of the present invention is its ability to eliminate toxic byproducts. For example, where NaCl-based solid salt dosage forms are used to effect localized chemical ablation, the concentration is ultimately reduced to the level of normal saline (i.e., about 0.9%) upon absorption by the body of the subject being treated.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: June 5, 2007
    Assignee: Boston Scientific Scimed, Inc.
    Inventor: Joseph V. DiTrolio
  • Patent number: 7214381
    Abstract: The present invention refers to a pharmaceutical composition suitable for the transdermal or transmucosal administration of one or more active agents, in form of a gel or a solution, comprising as a permeation enhancers a combination of: a) saturated fatty alcohol of formula CH3—(CH2)n—CH2OH or saturated fatty acid CH3—(CH2)n—CH2COOH wherein n is an integer number 8÷22, preferably 8÷12, most preferably 10, or unsaturated fatty alcohol or fatty acid of formula: CH3(CnH2(n-1))—OH or CH3(CnH2(n-1))—COOH wherein n is an integer number 8÷22, b) a ternary vehicle or carrier consisting of a C1÷C4 alkanol, a polyalcohol in particular propylenglycol and water, c) optionally also a monoalkylether of diethylenglycol.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: May 8, 2007
    Assignee: Antares Pharma IPL AG
    Inventors: Dario Carrara, Gabriel Porto, Jorge Rodriguez
  • Patent number: 7166605
    Abstract: Probucol derivatives and pharmaceutical compositions containing the same to be employed in treatment or prophylaxis of diseases.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: January 23, 2007
    Assignee: Nicox, S.A.
    Inventors: Piero Del Soldato, Giancarlo Santus, Ennio Ongini
  • Patent number: 7135190
    Abstract: A water soluble, biodegradable reverse thermal gelation system comprising a mixture of at least two types of tri-block copolymer components is disclosed. The tri-block copolymer components are made of a hydrophobic biodegradable polyester A-polymer block and a hydrophilic polyethylene glycol B-polymer block. The drug release and gel matrix erosion rates of the biodegradable reverse thermal gelation system may be modulated by various parameters such as the hydrophobic/hydrophilic component contents, polymer block concentrations, molecular weights and gelation temperatures, and weight ratios of the tri-block copolymer components in the mixture.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: November 14, 2006
    Assignee: Macromed, Inc.
    Inventors: Ai-Zhi Piao, Chung Shih
  • Patent number: 7135191
    Abstract: The invention is directed to a suppository based vaccine delivery system for immunizing against urogenital and anorectally transmitted infectious disease in humans and animals and a method for treating the same. More particularly, this invention is directed to a suppository based vaccine delivery system for the prophylaxis against or treatment of urogenital or anorectal transmitted infectious diseases, such as from viral or microbial pathogens.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: November 14, 2006
    Inventors: Zsolt Istvan Hertelendy, Murray Weiner, Michael Howell, Joseph Thomas
  • Patent number: 7087249
    Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: August 8, 2006
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
  • Patent number: 7056495
    Abstract: The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose delivery vehicle of the invention.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: June 6, 2006
    Assignee: Quadrant Drug Delivery Ltd.
    Inventors: Bruce J. Roser, Jaap Kampinga, Camilo Colaco, Julian Blair
  • Patent number: 7045140
    Abstract: Metal carbonyls are used to deliver CO having biological activity, for example vasodilatation and inhibition of transplant rejection. The metal of the carbonyl is typically of groups 7 to 10, e.g. Fe and Ru. The carbonyl preferably has one or more ligands other than CO, such as amino acids, to modulate the CO release property and solubility.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: May 16, 2006
    Assignee: Hemocorm Limited
    Inventors: Roberto Angelo Motterlini, Brian Ernest Mann
  • Patent number: 7022335
    Abstract: A suppository of retaining in a lower region of rectum, which contains a suppository base containing: (A) a fatty acid triglyceride, (B) one or more C14-18 fatty acid glycerides, and (C) a base ingredient for retaining the suppository in the lower region of rectum, has quite high safety, does not melt by the body temperature when it is held by the fingers before insertion into the rectum so that it is easy to handle, does not deform by elevation of temperature during storage, and prevents stimulation to the rectum mucosa such as congestive hemorrhage and expansion of the rectum mucosa after the insertion.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: April 4, 2006
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Seiichi Hori, Katsuyoshi Aikawa
  • Patent number: 7001609
    Abstract: The present invention is directed to mucosal originated drug delivery systems and methods for using the drug delivery system to treat conditions in animals. Conditions amenable to treatment according to the invention are also described. The described mucosal drug delivery systems provide for drug release across a mucosal membrane as well as release away from the mucosal membrane.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: February 21, 2006
    Assignee: Regents of the University of Minnesota
    Inventors: Charles J. Matson, Yen-Lane Chen, Daniel T. Ruth, Luce R. M. Benes, Sophie G. Burgaud, Francoise L. R. Horriere, Isabelle M. L. Seyler
  • Patent number: 6986901
    Abstract: The invention relates to compositions and methods for treating and/or preventing lower gastrointestinal (GI) disorders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with such disorders.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: January 17, 2006
    Assignee: Warner-Lambert Company LLC
    Inventors: Gerard M. Meisel, Arthur A. Ciociola
  • Patent number: 6962717
    Abstract: A pharmaceutical composition for slow release of active ingredient in the gastrointestinal tract, comprising a plurality of active ingredient-containing particles coated with a material insoluble in gastric and intestinal juices, where the particles have as core a homogeneous mixture comprising an active pharmaceutical ingredient and a polymer insoluble in gastric and intestinal juices, with an average internal pore diameter not exceeding 35 ?m, makes efficient and pH-independent delaying of release possible even with comparatively small amounts of polymer. It is additionally distinguished by a long shelf life and is particularly suitable also for nonspherical particles.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: November 8, 2005
    Assignee: Disphar International B.V.
    Inventors: Gerald Huber, Peter Gruber
  • Patent number: 6949255
    Abstract: The present invention provides methods for preventing the transmission of HIV, methods for prophylaxis of HIV transmission and methods for reducing the risk of HIV transmission vaginally or rectally using compositions having at least one of polyquaternium, glycerin, methylparaben or proplyparaben. The invention further provides methods for inhibiting the transmission of a sexually transmitted disease using the compositions. Additionally, the invention provides combinations of compositions and devices used with such methods.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: September 27, 2005
    Assignee: Board of Regents, University of Texas
    Inventors: Samuel Baron, Miles W. Cloyd, Joyce Poast, Derrick Nguyen
  • Patent number: 6939563
    Abstract: Use of a non-fermented osmotic laxative as an active agent for preparation of a medicinal product for treating and/or preventing colon and/or rectum cancers. A method of treating or preventing colon or rectum cancer comprising administering to a mammal a therapeutically effective amount of a non-fermented osmotic laxative.
    Type: Grant
    Filed: April 18, 2001
    Date of Patent: September 6, 2005
    Assignees: Inra-Institut National de la Recherche Agronomique, ENVT-Ecole Nationale Veterinaire de Toulouse
    Inventors: Denis Corpet, Sylviane Tache, Géraldine Parnaud
  • Patent number: 6923988
    Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: August 2, 2005
    Assignee: Lipocine, Inc.
    Inventors: Mahesh V. Patel, Feng-Jing Chen
  • Patent number: 6899888
    Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: May 31, 2005
    Assignee: Otx, Inc.
    Inventors: Mitchell S. Steiner, Karen A. Veverka
  • Patent number: 6890547
    Abstract: By blending glycyrrhizin with an ester mixture comprising a C6-18 fatty acid glycerol ester with a C6-18 fatty acid macrogol ester, glycyrrhizin can be efficiently absorbed via mucosae, in particular, digestive mucosae to achieve a therapeutically effective plasma glycyrrhizin concentration.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: May 10, 2005
    Assignee: Amato Pharmaceutical Products, Ltd.
    Inventors: Kanji Takada, Masahiro Murakami
  • Patent number: 6861060
    Abstract: Personal care and hygiene formulations for topical application to mucosal surfaces. These formulations include an amphiphilic lipid carrier in the form of a colloidal composition which can include a micellar aggregate or mixed micelles dispersed in a continuous aqueous phase, or an emulsion of lipid droplets suspended in a continuous aqueous phase, and an active agent which is an anti-microbial agent. The lipid carrier has high adhesiveness to mucous membranes such as the soft tissues of the oral cavity. The lipid carrier also has a high load capacity for the active agent to be carried to these tissues. These formulations have the desirable properties of carrying a large amount of active agent for controlled and prolonged release thereof at the desired site, such as mucous membrane surfaces and surrounding tissue. Accordingly, the present invention provides a formulation for oral or topical application including an anti-microbial agent and a lipid.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: March 1, 2005
    Inventors: Elena Luriya, Leonid Luriya
  • Patent number: 6861066
    Abstract: A method of manufacturing a stable nanosuspension for delivery of a biologically active agent into the bloodstream of a subject is disclosed. A microfluidizable mixture is initially formed and processed via a microfluidization process to form the stable nanosuspension, which may be administered via the buccal mucosa or other suitable routes of administration. This product demonstrates increased bioavailability, enhanced period of onset, and enhanced stability for a controlled-release product.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: March 1, 2005
    Assignee: Health Plus International Inc.
    Inventor: Russell Van de Casteele
  • Patent number: 6841169
    Abstract: The present invention relates to an auxiliary substance for an active substance, such as a pharmacon. The auxiliary substance has a stabilizing action. The auxiliary substance further has a positive influence on the bioavailability of the active substance with which the auxiliary substance can be incorporated into a pharmaceutical preparation. The auxiliary substance is based on a fructan having a number-average degree of polymerization of at least 6 and is used in the form of a sugar glass.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: January 11, 2005
    Assignee: Rijksuniversiteit Groningen
    Inventors: Wouter Leonardus Joseph Hinrichs, Henderik Willem Frijlink
  • Publication number: 20040209966
    Abstract: An aqueous air foam comprising a non-crosslinked cellulose ether selected from C1-C3-alkyl celluloses, C1-C3-alkyl hydroxy-C1-3-alkyl celluloses, hydroxy-C1-3-alkyl celluloses, or mixed hydroxy-C1-C3-alkyl celluloses, the foam having a foam quality FQ of from 60 to 97 percent and the foam quality being defined as FQ(%)=[air volume/(air volume+fluid volume)×100].
    Type: Application
    Filed: May 27, 2004
    Publication date: October 21, 2004
    Inventors: Paul J. Sheskey, Colin M. Keary
  • Patent number: 6800663
    Abstract: The present invention relates to crosslinked polymers, synthesized through ring-opening polymerization of ethylenically unsaturated epoxides, in combination with &agr;-hydroxy acids using a hydrophilic macroinitiator, such as poly(ethylene glycol), to form substituted copolymers having ethylenically unsaturated functionality randomly distributed along the polyester polymer backbone. That copolymer is subsequently crosslinked to form a hydrogel network. More particularly, the present invention relates to the synthesis of biodegradable poly(&agr;-hydroxy acid-co-glycidyl methacrylate)-block-poly(ethylene glycol)-block-poly(&agr;-hydroxy acid-co-glycidyl methacrylate) copolymers, which are subsequently crosslinked to form hydrogel networks. The invention also relates to the use of these hydrogel networks in various applications, in particular, for the controlled release of drugs and proteins.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: October 5, 2004
    Assignee: Alkermes Controlled Therapeutics Inc. II,
    Inventors: Firouz Asgarzadeh, Henry R. Costantino
  • Patent number: 6761903
    Abstract: The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: July 13, 2004
    Assignee: Lipocine, Inc.
    Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fikstad
  • Patent number: 6749856
    Abstract: The invention provides methods for induction of an antigen-specific, mucosal cytotoxic T lymphocyte response useful in preventing and treating infections with pathogens that gain entry via a mucosal surface.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: June 15, 2004
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Igor M. Belyakov, Michael A. Derby, Brian L. Kelsall, Warren Strober
  • Patent number: 6740333
    Abstract: There is provided a suppository comprising at least one biocompatible polymer, wherein the biocompatible polymer is essentially non-biodegradable, and wherein the suppository essentially does not swell when contacted with an aqueous fluid. The suppository may further comprise a plurality of open cells at least partly separated from one another by an interpenetrating matrix comprising at least one biocompatible polymer in branched or crosslinked form. The plurality of interlinked, open cells are capable of containing an aqueous fluid, and the permeability of the suppository ensures that entry of body fluids into the open cells under practical circumstances occurs essentially without dehydration of mucousal membrane tissue contacting the suppository. The suppository furthermore preferably comprises a controlled release formulation.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: May 25, 2004
    Assignee: Anestic ApS
    Inventors: Christian Westy Beckett, Per Robert Topp Eliasen
  • Patent number: 6730322
    Abstract: A lipid or other hydrophobic or amphiphilic compound (collectively referred to herein as “hydrophobic compounds”) is integrated into a polymeric matrix for drug delivery to alter drug release kinetics. In embodiments where the drug is water soluble, the drug is released over longer periods of time as compared to release from the polymeric matrix not incorporating the hydrophobic compound into the polymeric material. In contrast to methods in which a surfactant or lipid is added as an excipient, the hydrophobic compound is actually integrated into the polymeric matrix, thereby modifying the diffusion of water into the microparticle and diffusion of solubilized drug out of the matrix. The integrated hydrophobic compound also prolongs degradation of hydrolytically unstable polymers forming the matrix, further delaying release of encapsulated drug.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: May 4, 2004
    Assignee: Acusphere, Inc.
    Inventors: Howard Bernstein, Donald Chickering, Sarwat Khattak, Julie Straub
  • Patent number: 6723336
    Abstract: The present invention relates to the treatment of gastrointestinal disease and/or cancer, and a method of weight gain, via the ingestion of polymeric compositions in humans, animals or birds in need of said treatment. The invention provides methods for the treatment of cancer, the treatment and/or prevention of gastrointestinal disease and/or infection and/or diarrhea and a method for increasing weight gain in humans, animals or birds comprising administering to said humans, animals or birds an effective amount of a pharmaceutical or veterinary composition or feed additive, comprising an effective amount of a polymer and/or copolymer, having the repeating polymeric unit (I) wherein R is H or alkyl, usually C1 to C4, or this unit in hydrated, hemiacetal or acetal form, together with a pharmaceutically or veterinarally acceptable carrier, diluent, adjuvant, excipient and/or controlled release system.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: April 20, 2004
    Assignee: Chemeq Ltd.
    Inventor: Graham John Hamilton Melrose
  • Patent number: 6699495
    Abstract: Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Desmethylselegiline is the R-(−) enantiomer of N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane. Claimed compositions include both the R-(−) isomer and mixtures of the R-(−) and S(+) isomers. Pharmaceutically acceptable acid addition salts may also be used. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 2, 2004
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Cheryl D. Blume, Anthony R. DiSanto
  • Patent number: 6696071
    Abstract: An aqueous douche or enema is disclosed, containing a water-soluble zinc salt at an anti-viral concentration, designed for use shortly before and/or shortly after intercourse. Unlike a lubricant for use during intercourse, this type of rinsing liquid will not contain glycerine or similar lubricating components, and will be designed to not leave behind a film-type residue. However, this type of “pericoital” rinse (i.e., intended for pre-coital or post-coital use) will leave behind positively-charged zinc ions. Due to electrostatic attraction, these Zn++ ions will cling to negatively-charged canyons and other “binding sites” in proteins that are exposed and accessible on the surfaces of cells and virus particles. The binding of Zn++ ions to negatively-charged sites in these surface proteins will alter and disrupt the ability of viruses (including herpes and HIV) to bind to and infect human cells.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: February 24, 2004
    Inventor: Patrick D. Kelly
  • Patent number: 6669951
    Abstract: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: December 30, 2003
    Assignee: CellGate, Inc.
    Inventors: Jonathan B. Rothbard, Paul A. Wender, P. Leo McGrane, Lalitha V. S. Sista, Thorsten A. Kirschberg
  • Patent number: 6667058
    Abstract: Pharmaceutical dosage units containing flupirtine or a pharmaceutically acceptable salt of flupirtine with controlled release of active substance using a delayed-action or controlled-release component. There are 0.001 to 20 parts delayed-action component for each part by weight flupirtine (calculated as the base) and the release rate of flupirtine is between 5 and 300 mg per hour. In some cases, the dosage units may also contain a rapidly releasing component of flupirtine or of one of its salts. The dosage units reduce the sedative effect of flupirtine.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: December 23, 2003
    Assignee: Viatris GmbH & Co. KG
    Inventors: Joachim Goede, Helmut Hettche, Helmut Momberger, Jürgen Engel, Michael Lobisch
  • Patent number: 6652884
    Abstract: The invention concerns a method for the treatment of tumors sensitive to Paclitaxel, by intra-arterial injections of dispersions of microparticles of albumin incorporating Paclitaxel in physiological solutions.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: November 25, 2003
    Assignee: ACS Dobfar S.p.A.
    Inventor: Marco Falciani
  • Patent number: 6638498
    Abstract: Improved molecularly imprinted polymers (MIPs) with both higher and more specific binding capacity for particular bile acids and/or salts, including the synthesis of such MIPs, the compounds themselves, and specific applications thereof. As an example of a particularly preferred specific application of these compounds, the present invention encompasses the use of the MIPs as sequestrants in the gastrointestinal tract, particularly in order to bind and therefore remove toxins from the gastrointestinal tract. In addition, the present invention is also useful for treatment of various diseases which are related to, and/or characterized by, an effect of bile acids and salts, such as atherosclerosis, liver disease and various diseases of the gastrointestinal tract. The MIP compounds of the present invention are also useful for combination therapy with other medications and for diagnosis and monitoring of diseases.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: October 28, 2003
    Assignee: Semorex Inc.
    Inventors: Bernard S. Green, Morris Priwler
  • Patent number: 6607742
    Abstract: Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: August 19, 2003
    Assignee: Altana Pharma AG
    Inventors: Rudolf Linder, Rango Dietrich
  • Patent number: 6602519
    Abstract: The present invention relates to the use of oxidized thymosin &bgr;4 in therapy, more particularly in the treatment of diseases or conditions associated with an inflammatory response of septic shock.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: August 5, 2003
    Assignees: The University Court of the University of Glasgow, Imperial Cancer Research Technology
    Inventors: Robert Duncan Stevenson, Anthony John Lawrence, John Young, Darryl John Cecil Pappin
  • Patent number: 6596297
    Abstract: An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one pectin, such as an apple pectin, and optionally at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: July 22, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander Robert Neurath, Nathan Strick
  • Patent number: 6592894
    Abstract: A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: July 15, 2003
    Assignees: BioDelivery Sciences International, Inc., University of Medicine and Dentistry of New Jersey
    Inventors: Leila Zarif, Tuo Jin, Ignacio Segarra, Raphael J. Mannino
  • Patent number: 6585996
    Abstract: The present invention is directed to a method for the treatment of autism comprising administering to a person in need of such treatment a therapeutically effective amount of a lipid-soluble thiamine derivative. The lipid-soluble thiamine derivative is preferably tetrahydrofurfuryl disulfide (TTFD). TTFD administration methods may include suppository forms, transdermal carriers, such as gels, lotions, or creams; and oral carriers, such as tablets or capsules.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: July 1, 2003
    Assignee: Westlake Laboratories, Inc.
    Inventors: Derrick Lonsdale, James P. Frackelton
  • Patent number: 6576250
    Abstract: The pharmaceutical compositions of the present invention comprise rectally and vaginally administerable dosage forms that contain effervescent agents as penetration enhancers for drugs. Effervescence occurs in the rectum or vagina, once the dosage form is administered or at a predetermined time following administration. The effervescent agents can be used alone or in combination with pH adjusting substance, which further promote dissolution and absorption of the active ingredient.
    Type: Grant
    Filed: September 19, 2000
    Date of Patent: June 10, 2003
    Assignee: Cima Labs Inc.
    Inventors: S. Indiran Pather, Joseph R. Robinson, Jonathan D. Eichman, Rajendra K. Khankari, John Hontz
  • Patent number: 6572875
    Abstract: An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: June 3, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander Robert Neurath, Nathan Strick
  • Patent number: 6569463
    Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: May 27, 2003
    Assignee: Lipocine, Inc.
    Inventors: Mahesh V. Patel, Feng-Jing Chen
  • Patent number: 6565871
    Abstract: The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose of the invention.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: May 20, 2003
    Assignee: Elan Drug Delivery Ltd.
    Inventors: Bruce J. Roser, Jaap Kampinga, Camilo Colaco, Julian Blair
  • Patent number: 6565889
    Abstract: The present invention provides compositions and methods of preparing a bilayer structure for encapsulating multiple containment units. These containment units can contain therapeutic, diagnostic agents or imaging agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: May 20, 2003
    Assignee: The Regents of the University of California
    Inventors: Joseph A. Zasadzinski, Scott A. Walker, Michael T. Kennedy, Edward T. Kisak, Bret A. Coldren
  • Patent number: 6555126
    Abstract: This invention pertains to a method that can control, treat, and prevent Diabetes Mellitus. The method includes means of administering a potent product, including mainly the active ingredient Linalool, in any one of several forms, alone or with other additives and catalysts, such as vitamin E to enable the body to handle and control, then correct the complications of Diabetes Mellitus. A modest percentage of users suffering from this disease can be cured completely while the majority of others improve remarkably and experience lower blood glucose and reduce the glycated hemoglobin HbAlc readings to what are medically acceptable and healthy levels. Others, who are vulnerable to the disease due to hereditary factors, or other reasons, can help prevent it. The method works in several ways, including activation of the pancreas and re-establishing the ability of body cells to utilize and handle better and well, the glucose in the blood, and regulate the level of natural insulin in the body.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: April 29, 2003
    Assignee: Diabex, Inc.
    Inventors: Osama Mansour Murad, Husni Abu Seir, Hafez Taji Farouqi
  • Patent number: 6544550
    Abstract: The invention relates to the co-administration in human or veterinary medicine of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof and dexamethasone or a physiologically acceptable salt or ester thereof. The two active ingredients, which may be administered separately either simultaneously or sequentially, or may be combined in a single pharmaceutical preparation, are useful in the relief and/or prevention of nausea and vomiting.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: April 8, 2003
    Assignee: Glaxo Group Limited
    Inventors: Michael Brian Tyers, Teresa Elizabeth Challoner
  • Patent number: 6528082
    Abstract: The application is directed to the treatment of neoplastic diseases or conditions by administering R(−) desmethylselegiline, S(+) desmethylselegiline, or a combination of the two. Neoplastic diseases and conditions responsive to R(−) desmethylselegiline and/or S(+) desmethylselegiline include both malignant and benign neoplasms.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: March 4, 2003
    Assignee: Somerset Pharmaceuticals, Inc.
    Inventors: Cheryl D. Blume, Anthony R. DiSanto